By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Anika Therapeutics 

32 Wiggins Avenue

Bedford  Massachusetts  01730   U.S.A.
Phone: 781-457-9000 Fax: 781-935-4120

Anika Therapeutics is a pioneer in developing therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. HA also is present in the skin, where it supports skin structure and elasticity. With more than 20 years of experience in HA technology, Anika is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

Anika manufactures and distributes a diverse portfolio of HA-based products that cover a broad range of therapeutic applications. These products include ORTHOVISC®, ORTHOVISC® mini, and MONOVISC™ used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; the ELEVESS™ family of cosmetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™ II, and OPTIVISC™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; and next-generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.

Key Statistics

Ownership: Public

Web Site: Anika Therapeutics
Symbol: ANIK


Company News
Anika Therapeutics (ANIK) Delivers Solid Second Quarter 2015 Financial Results And Continued Pipeline Progress 7/30/2015 1:03:10 PM
Anika Therapeutics (ANIK) To Issue Second Quarter 2015 Financial Results And Business Highlights On Wednesday, July 29 7/15/2015 10:37:38 AM
Anika Therapeutics (ANIK) Announces Positive Results From Follow-Up Study Evaluating Safety Of A Repeat Injection Of CINGAL For Treatment Of Osteoarthritis Of The Knee 7/9/2015 7:38:24 AM
Anika Therapeutics (ANIK) Files Investigational Device Exemption To Initiate Phase III Study To Expand Indication Of MONOVISC To Treat Pain Caused By Osteoarthritis Of The Hip 6/23/2015 9:56:57 AM
Anika Therapeutics (ANIK) Announces Strategic Collaboration With The Institute For Applied Life Sciences (IALS) At The University of Massachusetts - Amherst 6/17/2015 9:07:17 AM
Anika Therapeutics (ANIK) To Present At Jefferies and Co. 2015 Global Healthcare Conference On June 4 5/22/2015 6:35:15 AM
Anika Therapeutics (ANIK) Announces Presentation Of Seven Abstracts At 12th Annual World Congress Of The International Cartilage Repair Society 4/29/2015 12:14:28 PM
Anika Therapeutics (ANIK) Reports First-Quarter 2015 Financial Results 4/29/2015 12:12:20 PM
Anika Therapeutics (ANIK)' Cingal 13-02 Study Meets Primary Endpoint 4/20/2015 6:42:43 AM
Anika Therapeutics (ANIK) Reports On Cingal 13-01 Study Clinical Trial Top Line Data And Announces The Completion Of Cingal 13-02 Study’s Patient Enrollment 4/17/2015 8:56:29 AM